title: Radiation dose enhancement of gadolinium-based AGuIX nanoparticles on HeLa cells.
abstract: Radiation dose enhancement of high-Z nanoparticles is an active area of research in cancer therapeutics. When kV and MV energy photon beams interact with high-Z nanoparticles in a tumor, the release of secondary electrons can injure tumor cells, leading to a higher treatment efficacy than radiation alone. We present a study that characterizes the radiation dose enhancing effects of gadolinium-based AGuIX nanoparticles on HeLa cells. Our in vitro clonogenic survival assays showed an average dose enhancement of 1.54× for 220 kVp radiation and 1.15× for 6 MV radiation. The sensitivity enhancement ratio at 4 Gy (SER4Gy) was 1.54 for 220 kVp and 1.28 for 6 MV, indicating that these nanoparticles may be useful for clinical radiation therapy.
  
  
  BACKGROUND
  This study characterized the radiation dose enhancing effects of gadolinium-based AGuIX nanoparticles on HeLa cells, showing clear effects at 220 kV as well as 6 MV, suggesting that after additional studies, these nanoparticles may be beneficial in human radiation therapy.
authors.affiliation: Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA. Electronic address: mfluchet@gmail.com.
authors.forename: Matthew
authors.initials: M
authors.lastname: Luchette
authors.affiliation: Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA.
authors.forename: Houari
authors.initials: H
authors.lastname: Korideck
authors.affiliation: Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA.
authors.forename: Mike
authors.initials: M
authors.lastname: Makrigiorgos
authors.affiliation: Institut Lumière Matière, CNRS, Universite Claude Bernard Lyon 1, Villeurbanne, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Tillement
authors.affiliation: Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA.
authors.forename: Ross
authors.initials: R
authors.lastname: Berbeco
mesh_terms: D002470:Cell Survival / Q000528:radiation effects; D005682:Gadolinium / Q000737:chemistry*; D006046:Gold / Q000737:chemistry*; D006367:HeLa Cells; D006801:Humans; D053768:Metal Nanoparticles / Q000737:chemistry*; D011829:Radiation Dosage
chemical_list: D006046:Gold; D005682:Gadolinium
keywords: Dose enhancement; Nanoparticles; Radiation oncology